In a Landmark Decision, China's Supreme Court Reverses Lower Court Decision Banning Excessively High Prices on a Patent-Protected Pharmaceutical Product | Insights

China's Supreme People's Court found that because the price of the end product containing loratadine actually decreased during the period at issue, HIPI Pharma Tech's actions did not cause harm to consumers.

Related Keywords

China ,Yangtze River ,China General ,Yangtze , ,Yangtze River Pharmaceutical Group ,National Medical Products Administration ,Supreme People Court ,Supreme People ,Anti Monopoly Law ,